Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 3/20 | 0.65 |
| ▸ | CA1 | P00915 | 3/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | CA7 | P43166 | 3/20 | 0.65 |
| ▸ | CA9 | Q16790 | 3/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113092 | 0.96 | ALDH1A1 (1.00) | ALDH1A1MAPK1SMN1; SMN2HSD17B10CA12 | |
| SCHEMBL24624914 | 0.90 | ALDH1A1 (0.83) | ALDH1A1MAPK1SMN1; SMN2CA12CA1 | |
| SCHEMBL23016876 | 0.84 | ALDH1A1 (0.74) | ALDH1A1MAPK1SMN1; SMN2CA12CA1 | |
| SCHEMBL10113275 | 0.83 | ALDH1A1 (0.80) | ALDH1A1MAPK1SMN1; SMN2CA12CA1 | |
| SCHEMBL19752667 | 0.79 | KIF11 (0.75) | MAPK1HSD17B10CA12CA1CA2 | |
| SCHEMBL5347891 | 0.79 | KIF11 (0.75) | MAPK1HSD17B10CA12CA1CA2 | |
| SCHEMBL18025267 | 0.79 | KIF11 (0.75) | MAPK1HSD17B10CA12CA1CA2 | |
| SCHEMBL10112945 | 0.77 | CA1 (0.78) | ALDH1A1MAPK1SMN1; SMN2CA12CA1 | |
| SCHEMBL19752712 | 0.77 | MEN1 (0.67) | ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL19752713 | 0.77 | MEN1 (0.67) | ALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | ALDH1A1 313/4885MAPK1 1736/4885SMN1; SMN2 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.